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Sildenafil citrate (SILC) is a potent phosphodiesterase-5 inhibitor used for erectile dysfunction and 
pulmonary hypertension. This study shows two simple, fast and alternative analytical methods for SILC 
determination by non-aqueous titration and by derivative ultraviolet spectrophotometry (DUS) in active 
pharmaceutical ingredient and/or dosage forms. The quantitation method of SILC active pharmaceutical 
ingredient by non-aqueous acid-base titration was developed using methanol as solvent and 0.1 mol/L of 
perchloric acid in acetic acid as titrant. The endpoint was potentiometrically detected. The non-aqueous 
titration method shows satisfactory repeatability and intermediate precision (RSD 0.70-1.09%). The 
neutralization reaction occurred in the stoichiometric ratio 1:1 in methanol. The determination of SILC 
active pharmaceutical ingredient or dosage forms by DUS was developed in the linear range from 10 
to 40 µg/mL, in 0.01 mol/L HCl, using the first order zero-peak method at λ 256 nm. The DUS method 
shows selectivity toward tablets excipients, appropriate linearity (R2 0.9996), trueness (recovery range 
98.86-99.30%), repeatability and intermediate precision in three concentration levels (RSD 1.17-1.28%; 
1.29-1.71%, respectively). Therefore, the methods developed are excellent alternatives to sophisticated 
instrumental methods and can be easily applied in any pharmaceutical laboratory routine due to simple 
and fast executions.
Uniterms: Sildenafil citrate. Vasodilator. Derivative ultraviolet spectrophotometry. Non-aqueous acid-
base titrimetry. Sildenafil citrate/quality control.
INTRODUCTION
Sildenafil citrate (SILC, Figure 1) is a potent 
5-fosfodiesterase (PDE-5) inhibitor with a pharmacological 
effect through an increase in intracellular concentration 
of cyclic guanosine monophosphate (cGMP), a potent 
vasodilator. SILC is a compound of the pyrazolo-
pyrimidinyl-methyl piperazine class used not only for 
erectile dysfunction treatment but also for pulmonary 
arterial hypertension (Escribano, Jimínez, Calzada, 2005; 
American College of Cardiology Foundation; American 
Heart Association, 2009; Galiè et al., 2010, Sawatdee, 
Phetmung, Srichana, 2013).
Since the patent of the reference medicine Viagra® 
(Pfizer Laboratories Ltd.) expired in 2010, many generic 
drug companies were able to bring out to the market similar 
dosage forms with lower prices. Moreover, the trend of the 
number of pharmaceutical companies around the world, 
that will produce drugs containing SILC, is to increase. 
Compounding pharmacies also aim the production in a 
smaller scale of the different formula containing SILC, 
as their dispensation is commonly high due to the PDE-
5 inhibitor popularity. Therefore, in order to assure the 
manufacturing uniformity for the treatment of erectile 
dysfunction or pulmonary hypertension, as well as for quality 
FIGURE 1 - Chemical structure of vasodilator sildenafil citrate, 
MM 666.70 g/mol.
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control purposes, it is important to establish alternative 
validated methods that can be performed as a simple and 
fast drug quantitation in either the active pharmaceutical 
ingredient (API) or the pharmaceutical dosage forms. 
Furthermore, with a simple and fast development of 
standard analytical methods for SILC it is possible to 
support the pharmacovigilance, once SILC tablets have 
frequently been a target of contraband and counterfeit 
(Ortiz, Antunes, Linden, 2010; Ames, Souza, 2012).
There are several methods described in the literature 
for SILC API determination or dosage forms by various 
techniques. Most of these methods are based on the 
high-performance liquid chromatography (HPLC) or 
ultra-performance liquid chromatography (UPLC) using 
UV-Vis or mass detectors, however, they require several 
pieces of expensive reagents/equipments (Gratz, Flurer, 
Wolnik, 2004; De Orsi et al., 2009; Song, El-Demerdash, 
Lee, 2012; Damiano et al., 2014; Fejos et al., 2014).
Methods based on the formation of colored complexes 
for the determination of SILC in tablets have also been 
described by visible spectrophotometry (Amin, El-
Beshbeshy, 2001; Dinesh et al., 2002; Salem, 2006; 
Weinert, Pezza, Pezza, 2008; Issa et al., 2010; Frag, 
Mohamed, Alelaiwe, 2011a). Spectrofluorimetry and 
electroanalytical methods such as voltammetry using 
different electrodes were exploited by several researchers 
(Othman, Rizk, El-Shahawi, 2004; Hassan et al., 2006; 
Tyszczuk, Korolczuk, 2010; Wang et al., 2010; Balasoiu et 
al., 2011; Frag, Mohamed, Alelaiwe, 2011b; Wang, Gómez, 
Fernandez, 2013). However, these methods are laborious to 
be performed since they demand several types of reagents 
or sample treatment or involve many reactions steps and/or 
extraction processes for a quality control routine.
The titrimetry of several API based on chemical 
reactions of neutralization, oxi-reduction, precipitation 
or complexation can be found in the pharmacopeias. They 
show many advantages such as the ease of execution, 
a small consumption and simplicity/availability of 
reagents, the low cost, with precise and reliable results. 
Such features make the titration an excellent alternative 
to instrumental sophisticated analytical methods for the 
SILC raw material’s determination because it can be easily 
applied by any pharmaceutical company or compounding 
pharmacy in the drugs’ routine quality control.
The non-aqueous acid-base titrimetry is used more 
to quantify weak acids or bases, which do not provide a 
well-defined endpoint in the aqueous solvent. Moreover, 
this technique allows working with many water-insoluble 
substances when dissolved in appropriate organic solvents 
(USP, 2013a; BRITISH Pharmacopoeia, 2014). Pure 
substances can be titrated directly; however it is often 
necessary to isolate the API in pharmaceutical preparations 
from any interfering excipients. The environmental 
contamination and operator exposure to the organic 
solvents are reduced with the use of a small volume burette 
(such as 5.00 or 10.00 mL), or better, with the utilization 
of an automatic titrator, under the hood.
The derivative ultraviolet spectrophotometry (DUS) 
is widely used as an analytical tool in the medicines 
quality control for drug determination in multicomponent 
systems. This technique is simple and fast and allows 
the interference elimination of placebo, impurities or 
degradation products, improving the selectivity without 
a need of sample pre-treatment or drug extraction (Rojas, 
Ojeda, 2009; Donato et al., 2010).
A non-aqueous acid-base titrimetry and a DUS were 
chosen for the SILC analysis due to its simplicity and 
fastness. In addition, these analysis methods bear a lower 
cost, compared to methods such as liquid chromatography, 
and have a greater chance of application in compounding 
pharmacies and the majority of laboratory providers of 
routine quality control certificates.
Therefore, the aim of this work is to develop simple 
and alternative methods for the SILC API quantitation 
and dosage forms by titration in non-aqueous media and 
by DUS.
MATERIAL AND METHODS
Material and reagents
SILC working standard (99.69% purity; batch 
UT2100403; Ultratech India Limited, New Mumbai, India) 
and SILC 25 mg and 100 mg tablets (Sollevare®) were 
kindly donated by Vita Nova Institute (Hortolândia, SP, 
Brazil). Placebo was prepared using excipients: anhydrous 
calcium hydrogenated phosphate; hypromellose; 
magnesium stearate; lactose (Ipiranga Química, Santos, 
SP); blue aluminum lake color; croscarmellose sodium 
(Blanver, Taboão da Serra, SP); microcrystalline cellulose 
Microcel® MC102 (Colorcon do Brasil, São Paulo, SP); 
polyethylene glycol (PEG) 4000 (LabSynth, Diadema, 
SP); titanium dioxide (JB Química Indústria e Comércio 
Ltda, Suzano, SP, Brazil). Methanol (Tedia Company, 
Fairfield, IO, USA); hydrochloric acid; perchloric acid; 
glacial acetic acid (Merck, Darmstadt, Germany). All 
chemicals and reagents were of analytical grade.
Instrumental
An ultrasonic cleaner (1400, Unique; Indaiatuba, 
SP, Brazil), a centrifuge (Jouan B4i, Thermo Scientific; 
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Waltham, MA, USA), a dry oven (306/1, Fanem; São 
Paulo, SP, Brazil) were used. For the non-aqueous 
acid-base titrimetry of SILC raw material was used an 
automatic titrator (DL53, Mettler Toledo; Columbus, OH, 
USA) equipped with a burette (resolution 0.002 mL) and 
a proper combined glass electrode.
DUS method for the quantitation of SILC in bulk 
drug and tablets was performed in a Shimadzu 1800 UV-
Visible spectrophotometer (Shimadzu, Tokyo, Japan) with 
photodiode array detector. UV probe software version 2.33 
was used for data acquisition. The absorption spectra were 
scanned using 1 cm quartz cells.
SILC active pharmaceutical ingredient 
determination by non-aqueous acid-base 
titrimetry
For the non-aqueous acid-base titrimetry of the API 
about 200 mg of SILC, previously dried (105 °C, 5 h, dry 
heat), were accurately weighed and dissolved in 40 mL 
of solvent previously neutralized. The solvents tested 
were glacial acetic acid and methanol. The samples were 
sonicated for 10 min. A volumetric solution (VS) of 0.1 
mol/L HClO4 in acetic acid, previously standardized with 
potassium biphthalate, was used as titrant. The titration 
was preceded by 90 s of mechanical agitation in the 
automatic titrator for drug dissolution. The endpoint was 
indicated potentiometrically.
The repeatability and intermediate precision were 
evaluated by means of analysis of average content of six 
SILC replicates dissolved in methanol, in two days. 
SILC active pharmaceutical ingredient 
determination and dosage form by DUS
All SILC or placebo’s solutions were dissolved and 
diluted in 0.01 mol/L HCl. Parameters for the optimization 
were selected in the range from λ 200 to 400 nm. The 
absorption measurement in the first order of derivative (D1) 
using the zero-peak method was at λ 256 nm; the differential 
wavelength selected was λ 2 nm for a medium scan speed.
Validation
The parameters studied in the DUS method 
validation were selectivity, linearity, matrix effect, 
recovery, precision, detection limit, quantitation limit 
and robustness. These parameters were considered in 
order to verify the fitness for the purpose of the method 
(International Conference on Harmonization, 1996; 
Thompson, Ellison, Wood, 2002). The significance levels 
in hypothesis tests were α = 0.05.
The DUS method selectivity was evaluated using a 
placebo containing excipients commonly used in the SILC 
tablets manufacturing: anhydrous calcium hydrogenated 
phosphate (diluent, 36%); microcrystalline cellulose 
(diluent, 36%); croscarmellose sodium (disintegrant, 
5.0%); magnesium stearate (lubricant, 5.0%) and 
coating constituents as blue aluminum lake color (0.6%); 
hypromellose (0.5%); lactose (4.0%); PEG 4000 (0.1%) 
and titanium dioxide (0.4%).
To verify the selectivity in D1, SILC solutions of 
25 µg/mL and placebo were prepared in triplicate. The 
placebo solutions containing proportional amounts of 
excipients compared to a 25 µg/mL SILC from a dosage 
form solution were also prepared in the same solvent, 0.01 
mol/L HCl, in triplicate. SILC and placebo solutions were 
separately scanned and overlapped in the D1 in the range λ 
200-400 nm, and evaluated for any potential interference 
at λ 256 nm.
The DUS linearity method was evaluated using SILC 
standard solutions in the concentration range from 10 to 
40 µg/mL in 0.01 mol/L HCl. The calibration curve was 
prepared at five concentration levels, in three independent 
replicates. The ordinary least squares method (OLSM) was 
applied to the experimental data to estimate the regression 
parameters. This method assumes that the residuals are 
normally distributed, homoscedastic, independent of each 
other and that the model is linear (Draper, Smith, 1998). 
Violations of assumptions underlying OLSM residuals 
were evaluated by the following tests: residual normality 
by Ryan-Joiner, homoscedasticity by Brown-Forsythe and 
independence by Durbin–Watson; F tests were applied to 
check the regression significance and linearity deviation 
(Durbin, Watson, 1951; Souza, Junqueira, 2005). 
The matrix effect in the measurement of analyte 
concentration was investigated by the comparison of the 
slopes obtained for the solvent curve with that achieved 
for the matrix-matched curve by t test.
The DUS method validation for repeatability and 
intermediate precision was performed using SILC 25 mg 
tablets. SILC solutions at three levels of concentration, 10, 
25 and 40 µg/mL, correspondent to 40%, 100% and 160% 
of the working concentration (25 µg/mL) were prepared 
in 0.01 mol/L HCl, in triplicate. 
For the repeatability evaluation of DUS method, 
twenty units of SILC 25 mg tablets were crushed, and 
an accurately weighed portion of the powder, equivalent 
to one average weight, was transferred to a 100 mL 
volumetric flask followed by the addition of 60 mL of 
0.01 mol/L HCl. The dispersions were sonicated for 
10 min and the volume was completed with the same 
solvent to obtain the concentration 250 μg/mL. After 
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centrifugation (10 min, 4,000 rpm) aliquots removed from 
the supernatant of each stock solution were diluted to final 
concentrations 10, 25 and 40 µg/mL, in 0.01 mol/L HCl 
(each in triplicate). The precision, under repeatability 
and intermediate precision conditions, was estimated 
by ANOVA and expressed in terms of relative standard 
deviation (RSD) for the replicates of tablets samples 
at each level and in three different days (International 
Organization for Standardization, 1994). 
The method accuracy was reported as recovery 
percentage of known amount of SILC standard added to 
the placebo. An amount of 25 mg SILC standard was added 
to an equivalent mass of placebo, transferred to 100 mL 
volumetric flasks containing 60 mL of 0.01 mol/L HCl. The 
flasks were sonicated for 10 minutes and filled up to the 
mark with the respective solvents. The dispersions prepared 
in triplicate, were centrifuged (10 min, 4,000 rpm) and 
aliquots removed from the supernatant were diluted to final 
concentrations as described for the precision. The evaluated 
analytical method accuracy by recovery was calculated 
according to the equation %R=[CP/CS]×100, where CP 
is the concentration in a spiked dispersion of placebo, and 
CS is the standard solution concentration.
Limits of quantitation (LOQ), the lowest SILC 
concentration that can accurately be determined, was 
calculated by the equation LOQ = 10 sa/b, where sa is 
the standard deviation of the calibration curve intercept, 
a; b is the slope of the calibration curve (International 
Conference on Harmonization, 1996; FDA, 1994).
The DUS method robustness was evaluated by 
assay of sextuplicate 25 µg/mL solutions of SILC tablets 
and their reference solution in the working concentration 
25 µg/mL using different instrumentation: a HP8453 
UV-visible (Agilent Technologies, Inc., Santa Clara, CA, 
USA) with photodiode array detector and HP ChemStation 
software; and a Shimadzu 1800 UV-Visible with UV probe 
software version 2.33. The results obtained with the two 
spectrophotometers were compared by ANOVA and Tukey 
tests (α = 0.05).
RESULTS AND DISCUSSION
SILC active pharmaceutical ingredient 
determination by non-aqueous acid-base 
titrimetry
Due to the presence of the functional groups 
piperazine, pyrimidinone and pyrazole in the sildenafil 
molecule, as shown in Figure 2, four ionization sites are 
expected: three of which are basic centers (A, B, C) and 
one acid center (D). 
Gobry et al. (2000) have shown the determination 
of the ionization constant (pKa), in water/methanol, of 
the most basic nitrogen (A, piperazine, pKa 6.78) which 
shows sp3 hybridization and the pKa of a weak amide acid 
group (D, pyrimidinone, sp3, pKa 9.12). Hence, sildenafil 
is an amphoteric compound with a moderate basicity and a 
weak acidity for the ionization sites A and D, respectively. 
The authors mention that the ionization constants for the 
B and C groups were not determined due to uncertain 
basicity (Gobry et al., 2000; Wang, Chow, Zuo, 2008). On 
the other hand, the pKa of the salt molecule, SILC, for the 
tertiary protonated nitrogen of the piperazine ring, is found 
to be 8.7 as stated, for instance, in the drug’s reference 
book Clarke’s Analysis of Drugs and Poisons (Moffat, 
Osselton, Widdap, 2004).
The presence of such groups in the molecule leads to 
a partial ionization in aqueous solution and a low inflexion 
endpoint, therefore, requiring a non-aqueous medium for 
the acid-base titration. Thus, SILC basicity or acidity can 
be leveled at the hydroxilate or oxonium ions strength, if 
dissolved in a proper organic leveling solvent capable of 
evidencing their inflexion point.
In the present SILC acid-base titration in non-aqueous 
solvent, acidic amphiprotic glacial acetic acid was initially 
tested as the drug solvent because it is more commonly used 
in the determination of weak organic bases. The titration 
curve for the accurately weighed mass 200 mg of SILC in 
this solvent showed two inflection points, as shown in Figure 
3a and b in zero and first orders, respectively. The volumes 
of titrant consumed due to the presence of two equivalence 
points were detected in 2.89 mL and 6.36 mL, as evidenced 
in Figure 3a and b. Therefore, the stoichiometric ratio of the 
reaction was found to be 1 SILC to 2 HClO4. The volumetric 
factor found for the mass of the analyte reacted with the 
volume of titrant is equivalent to 33.336 mg of SILC per 
FIGURE 2 - Potential ionization sites of sildenafil (666.70 g/mol) 
in basic functional groups (A) piperazine, (B) pyrimidinone, 
(C) pyrazole and (D) weak amide acid group. (Adapted from 
Gobry et al., 2000).
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milliliter of 0.1 mol/L perchloric acid VS, i.e., each mL of 
titrant is equivalent to 33.336 mg of SILC.
The first endpoint was attributed to the citrate ion 
titration formed by SILC dissociation in the medium as 
long as the strongest basic group, A (Figure 2), present 
in the piperazine ring has already been protonated in 
the SILC molecule. Thus, the drug is titrated indirectly 
through its counterion, citrate and a displacement of the 
citrate ion of SILC takes place by the perchlorate ion. The 
second endpoint was attributed to the weak basic nitrogen 
titration (B, Figure 2) in the SILC pyrimidinone ring. In 
acetic acid, the titration of this group was possible because 
its strength was evidenced due to the solvent leveling effect 
for weak basic compounds.
Similarly, methanol, a neutral amphyprotic organic 
solvent, was used as a medium free of water for the SILC 
titration. Unlike observed using glacial acetic acid as 
solvent, the presence of only one inflection, hence, only 
one equivalence point was detected by the consumption 
of 2.70 mL of titrant for the same mass of SILC, due to 
titration of the citrate ion (Figure 4). 
The explanation for the observation of only one 
equivalence point in methanol is that this solvent presents 
a differentiation effect, so that the weak basic nitrogens are 
not titrated in SILC salt molecule. The stoichiometric ratio 
of titration reaction in this case is 1 SILC to 1 HClO4. The 
titre found for the mass of the analyte reacting with the 
volume of titrant is equivalent to 66.671 mg of SILC per 
milliliter of 0.1 mol/L perchloric acid VS.
The partial and global reactions of the SILC titration 
in acetic acid or methanol with 0.1 mol/L perchloric acid 
in acetic acid are shown in Figure 5. 
The chemical equation (Figure 5) shows that when 
the titrant is a strong acid such as perchloric acid dissolved 
in acetic acid, the latter can act as a base and accept protons 
donated by perchloric acid, forming acetic acid oxonium 
(CH3COOH2
+) and a very weak base, the perchlorate. The 
first endpoint of the non-aqueous SILC titration ([RN+H]
RCOO-), dissociated in protonated sildenafil (R3N
+H) and 
citrate ion (RCOO-) in either acetic acid or methanol, is 
attributed to the reaction of strong acetic acid oxonium. 
The species (CH3COOH2
+) easily donates protons to the 
strong base citrate and, a rapid reaction to regenerate acetic 
acid and citric acid occurs in the medium. Following the 
FIGURE 3 - Graphical representation of the non-aqueous 
titration curves in (a) zero and (b) first order using potentiometric 
endpoint detection for 200 mg of SILC in glacial acetic acid with 
volumetric solution of 0.1 mol/L of perchloric acid in acetic acid, 
as titrant. Volumes of titrant consumed in the two equivalence 
points detected were 2.89 mL and 6.36 mL.
FIGURE 4 - Graphical representation of the non-aqueous 
titration curves in (a) zero and (b) first order using potentiometric 
endpoint detection for 200 mg of SILC in methanol with 
volumetric solution of 0.1 mol/L perchloric acid in acetic acid, 
as titrant. Volumes of titrant consumed in the equivalence point 
was 2.70 mL.
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titrant addition, SILC takes up another mole of 0.1 mol/L of 
perchloric acid so that the stoichiometric ratio is 1:2 (drug 
to titrant), in acetic acid solvent (reaction of the second 
endpoint not shown). On the other hand, when SILC is 
dissolved in the differentiating solvent methanol there is no 
subsequent reaction and the stoichiometric ratio is 1:1. The 
global reaction shows the displacement of citrate counterion 
by perchlorate to produce sildenafil perchlorate. 
Hence, either solvent acetic acid or methanol can 
be used for the SILC titration of. The use of methanol as 
the organic solvent was selected due to a less irritant odor 
than acetic acid and the lower titrant consumption for the 
same mass of SILC. Therefore, the method using methanol 
contributes to a lower chemical residue production for the 
environment; however, it is up to the analyst to choose 
what is more convenient to their reality.
Six replicates of raw material dissolved in 
methanol were analyzed in two days for determination 
of repeatability (n=6) and intermediate (n=12) precision. 
The results for SILC precision and quantitation by non-
aqueous acid-base titrimetry are described in Table I.
The average content results for SILC determination 
comply with the established range of purity (98.0-102.0%) 
for the active ingredient, as described in the monograph for 
SILC raw material in United States Pharmacopeia (USP, 
2013b). The RSD found values were satisfactory (<1.0%) 
because they did not exceed 2% for repeatability, or 5% 
for intermediate precision in two days, what demonstrates 
that the method is adequately precise (Green, 1996, 
International Conference on Harmonization, 1996).
The goal of this work was to determine SILC API 
only, by non-aqueous titration as commonly seen in the 
general compendia for the weak bases assay (USP, 2013a). 
In case of solid dosage forms, it is noteworthy that the 
presence of certain excipients in solid dosage forms such as 
other basic compounds, calcium hydrogenated phosphate 
or magnesium stearate, can be a potential interference. 
Therefore, the drug must previously be extracted, as it 
is also the case for liquid pharmaceutical dosage forms, 
recommended by Beckett and Stenlake (1988).
SILC active pharmaceutical ingredient 
determination and dosage form by DUS
The DUS method has been used to determine 
pharmaceutical analytes in dosage forms due to the 
FIGURE 5 - General chemical reaction for the first endpoint of the non-aqueous SILC titration in acetic acid (following the 
titration takes up another drug to titrant stoichiometric ratio 1:2), as well as for the single endpoint of SILC titration in methanol 
(stoichiometric ratio 1:1) using 0.1 mol/L perchloric acid VS as titrant and potentiometric endpoint detection.
TABLE I - Precision results for SILC raw material (circa 200 mg) determination by non-aqueous acid-base titrimetry using methanol 
as the drug solvent, 0.1 mol/L HClO4 VS in acetic acid (concentration correction factor 0.9878) as titrant and potentiometric 
endpoint detection
Precision results Day 1 Day 2
Average volume (mL) of titrant ± SDa 3.04 ± 0.03 3.05 ± 0.02
Average content (%) ± SDa 100.51 ± 0.79 100.45 ± 0.57
Repeatability (%RSDa) 0.79 0.57
Intermediate precision (%RSDb) 0.66
a: SD, standard deviation, n = 6; RSD, relative standard deviation; b: n = 12.
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ease of interference elimination due to excipients and 
sometimes from degradation products. It is used for the 
simultaneous determination of drugs in associations, 
as well. This technique allows to extract qualitative 
and quantitative information from spectra composed 
of analytes overlapping bands and interfering with 
the advantages of being simple, fast, inexpensive and 
accessible to most analytical quality control laboratories 
(O’Haver et al. 1982; Rojas, Ojeda, 2009; Donato et al., 
2010).
In order to apply the DUS method not only for the 
drug quantitation, but also for the dissolution profile study, 
a 0.01 mol/L HCl solution was selected as the diluent 
solvent because the drug solubility is enhanced in acidic 
medium. In addition, this solvent is the one recommended 
as the medium for the SILC tablets’ dissolution profile 
study by the United States Food and Drugs Administration 
(Wang, Chow, Zuo, 2008; FDA, 2014; Badwan et al, 
2001).
During the method development, the spectra of 
standard SILC solutions (100% working concentration 25 
µg/mL) and placebo solutions (equivalent to the amount 
of excipients in the 25 µg/mL SILC solution) in the UV 
region were plotted in zero order and then overlapped 
in order to assess interferences from excipients present 
in proportions normally found in solid dosage forms 
containing SILC.
In the zero order spectrum, the placebo absorbs 
throughout the wavelength range that SILC absorbs, 
resulting in interference, as shown in Figure 6a. The 
percentage average of interference from placebo solution 
on SILC solution in the maximum absorption wavelengths 
λ 211 nm, 224 nm and 292 nm were 4.4; 4.1 and 7.2%, 
respectively. These values are well above the maximum 
acceptable for spectrophotometric methods, a value 
of 2.0%, according to recommendations of the United 
States Pharmacopeia (USP, 2013c). Therefore, it is not 
suitable to quantify SILC colored tablets by UV absorption 
spectrophotometry in the conventional mode.
The zero-peak derivative quantitation method 
was sought to reduce the systematic error in the SILC 
determination compared to the zero order, conventional 
method (Donato et al., 2010). Thus, the absorption spectra 
of zero (Figure 6a), first (Figure 6b), second (Figure 6c), 
third (Figure 6b) and fourth (Figure 6c) derivative of SILC 
and placebos were recorded and overlapped to determine 
the most appropriate wavelength, as well as the order of the 
derivative for quantitative SILC determination in tablets.
The UV absorption spectra for SILC in second, third 
and fourth orders of derivative represented in Figure 6 
shows that the UV spectra complexity increases as the 
order increases, nevertheless, the absorptivity significantly 
reduces as a consequence of impaired sensitivity. Thus, 
the first order derivative curves were chosen for the 
quantitation of the drug because it provides a greater 
FIGURE 6 - (a) UV absorption spectra overlay in zero order for 
SILC reference standard (SILC, 25 µg/mL) and a mixture of 
excipients (placebo, equivalent to the amount of excipients in 
the 25 µg/mL SILC solution) in 0.01 mol/L HCl; (b) in first order 
(Δλ=2 nm; scaling factor x1) and third order (Δλ=4 nm; scaling 
factor x10) and (c) second (Δλ=4 nm; scaling factor x1) and 
fourth order of derivative (Δλ=8 nm; scaling factor x1); medium 
scan speed for SILC reference standard (SILC, 25 µg/mL).
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sensitivity and a better signal-noise ratio compared to other 
orders of derivative, as shown in Figure 6 b, c.
Figure 7 shows the first order UV spectra of SILC 
with maximum or minimum absorption in λ 208 nm, 
221 nm, 238 nm, 256 nm, 272 nm and 313 nm. The peak 
with the highest amplitude is in λ 238 nm, where there 
is a small interference from placebo. The λ of greater 
amplitude, which coincides with the point of zero crossing 
absorption of placebo corresponds to the valley in λ 256 
nm. Therefore, the absorption at λ 256 nm in the first 
derivative was selected to quantify SILC in dosage form 
because at this λ elimination of excipients interference 
occurs.
The DUS parameters established after optimization 
of the SILC spectra at first order of derivative ultraviolet 
spectrophotometry were the average scan speed with a 
selected wavelength interval Δλ 2 nm. These conditions 
provided well-resolved spectra and precise first order 
absorbance results. The scan speed and the wavelength 
interval are critical and essential features in the method 
optimization since they influence the shape and the signal 
to noise ratio of the spectrum, as well as the method 
sensitivity (O’Haver, Begley, 1981; Morelli, 2003).
Validation
The method selectivity to the excipients was attested 
by the superposed spectra of the placebo and SILC 
reference standard solutions in the first order of derivative, 
in the described conditions. In the scanned spectrum for 
the placebo, a decreasing absorption is noticed from λ 
200 to approximately λ 253 nm, as shown in Figure 7. 
From λ 256 nm until λ 400 nm, it was possible to observe 
the elimination of such interference by using the zero-
peak method towards a mixture of excipients, commonly 
found in colored SILC tablets. Therefore, the absorbance 
measurement at λ 256 nm was selected.
For the linearity assessment the normality assumptions 
(Ryan-Joiner test), homoscedasticity (Brown-Forsythe test) 
and independence (Durbin-Watson test) of the regression 
residues were confirmed, as shown in Table II. The 
assumptions relative to residues were investigated by means 
of the hypotheses tests. For the normality assessment, the 
null hypothesis (Ho) tested was that the residues follow 
a normal distribution. If the value of the test statistic, the 
correlation coefficient (R) of the normal probability graph is 
greater than or equal to the critical R (tabulated), there is no 
evidence to reject Ho. For the homoscedasticity assessment, 
Ho was tested as if the residues variability were constant 
along the X-axis. For Ho confirmation, the test statistic, 
Levene t, tL, must be less than or equal to the critical tL. 
Finally, for the residual autocorrelation evaluation, Ho 
was tested as if the residues were independent. For Ho 
to be confirmed, the calculated value of the test statistic, 
Durbin-Watson d, must be between the two critical values, 
a lower limit, dL and an upper limit, dU (Durbin, Watson, 
1951; Brown, Forsythe, 1974; Ryan, Joiner, 1976; Draper, 
Smith, 1998; Souza, Junqueira, 2005).
FIGURE 7 - Overlay of first order UV spectra for SILC reference 
standard (SILC, 25 µg/mL) and placebo (equivalent to 25 µg/
mL SILC) in 0.01 mol/L HCl (wavelength range λ 200-400 nm; 
Δλ=2 nm; average scan speed).
TABLE II - Results and statistics for assumptions tests for linearity evaluation of the DUS method (Conditions: first order of 
derivative; zero-peak method, λ 256 nm; Δλ=2 nm; in 0.01 mol/L HCl; medium scan speed)
Assumption Statisticsd Critical Value Calculated Value
Normalitya R 0.9383 0.9683
Homoscedasticityb tL 2.160 0.562
Independencea dL; dU 1.07; 2.93 2.851
Regression significancec F 4.67 29,415.52
Lack of fitb F 3.71 0.067
a: p>0.10; b: p>0.05; c: p<0.001; d: R, correlation coefficient of the normal probability graph; tL, Levene t; dL, lower limit; dU, 
upper limit of Durbin-Watson; F, Fisher statistic.
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These results indicate the adequate estimation of 
the regression parameters by OLSM. The Fisher test, 
F, for the regression was significant (F>>critical F; p< 
0.001) while the lack of fit from linear model was not 
significant (F<critical F; p>0.05), indicating linearity 
in the studied concentration range from 10 to 40 µg/mL 
(Table II). The determination coefficient, R2 was 0.9996 
for the analytical curve equation y = (0.00111±0.00001)x 
+ (0.00018±0.0002).
No matrix effects were detected, because no 
significant differences were observed between the slopes 
achieved for the solvent and matrix-matched curves 
(p>0.05).
The method precision was expressed by the 
%RSD values of a series of measurements in three non-
consecutive days by different analysts. In Table III, the 
summarized results are shown for repeatability and 
intermediate precision for three levels of concentration 
(triplicate). The %RSD values obtained for repeatability 
and intermediate precision were satisfactory, not 
exceeding the maximum acceptable value of 2% or 5%, 
respectively (Green, 1996; International Conference on 
Harmonization, 1996).
The results for the trueness, evaluated by the 
standard addition method to the placebo and expressed as 
the percentage of recovery are shown in Table III. They 
indicate no lack of trueness, since the average recovery 
obtained for the replicates was within the range (98.0-
102.0%), as recommended by Green (1996) at each 
concentration level.
The estimated LOD and LOQ of the method, 
calculated by the equations using standard deviation of 
the curve intercept and the slope of the calibration curve 
were 0.48 and 1.58 µg/mL, respectively.
The DUS method robustness was evaluated by 
the parameter that has the greatest potential to interfere 
in the assay results generated by a DUS method, the 
differentiation program. The assay of sextuplicate 
sample solutions of SILC tablets (25 µg/mL, 0.01 
mol/L HCl) using two different spectrophotometers 
was performed for comparison of the obtained results 
by means of t test (α = 0.05). The equipments used to 
assess the method robustness have internal differentiation 
programs that operate in different modes. In the Agilent 
HP8453 software, it is not allowed to change important 
derivatization parameters such as Δλ and scanning speed, 
which are automatically selected and optimized. On the 
other hand, in the Shimadzu UV1800 software the user is 
able to select such parameters in order to assess the method 
optimization. 
The results for the DUS method robustness are 
shown in Table IV.
The calculated value for t statistic test (t=0.522) 
was lower than the critical value (t=2.228; α=0.05). Thus, 
there was no significant difference between the assay 
results for the SILC tablets pool analyzed in different 
spectrophotometers, what proves the method robustness.
In a study performed by El-Gindy et al. (2010), 
SILC was quantified by DUS in the concentration range 
from 4 to 36 µg/mL in the presence of four separate 
TABLE III - Precision and trueness results for SILC determination by DUS (first order of derivative; zero-peak method; λ 256 nm; 
Δλ=2 nm; in 0.01 mol/L HCl; medium scan speed)
Concentration
(µg/mL)
%RSDa
Repeatability  
(n = 3)
Intermediate 
precision, (n = 9)
%Recovery 
(%RSDa; n = 3) 
10 1.17 1.71 98.86 (0.98)
25 1.28 1.29 99.79 (1.61)
40 1.25 1.60 99.30 (1.61)
a: RSD, relative standard deviation.
TABLE IV - Robustness results for SILC determination by DUS 
(first order of derivative; zero-peak method; λ 256 nm; Δλ=2 
nm; in 0.01 mol/L HCl; medium scan speed)
Sample
Content (%)
Condition
HP8453 Shimadzu UV1800
1 98.82 99.10
2 99.25 99.33
3 98.17 98.38
4 99.30 99.79
5 99.57 100.03
6 96.50 97.01
Average; RSDa 98.60; 1.16 98.94; 1.12
a: RSD, relative standard deviation.
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impurities by first, second or third derivative order. 
Different wavelengths were chosen for the selective 
SILC determination in methanol:water (30:70) for each 
derivative order and for each impurity, by zero-peak 
methods or ratio spectra derivative (El-Gindy et al., 2010). 
Noteworthy, that method is not able to quantify the SILC 
in the presence of all four impurities simultaneously. 
Moreover, the interference towards excipients commonly 
found in SILC tablets was not appropriately evaluated. The 
authors ran only a recovery assay by means of standard 
addition to the tablets. A study of the matrix effect should 
have been conducted, as well as a careful evaluation of the 
spectral interference of excipients, the proper selection of 
λ, and the derivative order in which the interferences were 
null or minimal, in light of what was done in the present 
work.
Doubtless, the method developed by El-Gindy et 
al. (2010) is effective towards the SILC determination in 
the presence of its impurities, when evaluated separately. 
Therefore, the method shows limited applicability and 
the validation protocol is incomplete, since it is necessary 
to evaluate the stability indication of the method for a 
formulation in the presence of its placebo.
The method developed to quantify SILC API or 
tablets in the described conditions was satisfactorily 
validated. The interference regarding the placebo including 
the blue dye present in SILC tablets was eliminated and 
carefully evaluated in the first derivative order by zero-
peak method, λ 256 nm. Moreover, the use of aqueous 0.01 
mol/L HCl as the drug diluent, hence, a chemical residue, 
is easy to neutralize or discharge and is less aggressive to 
the environment.
CONCLUSION
The SILC determination, such as API or as blue dyed 
tablets, by first derivative ultraviolet spectrophotometry 
showed no placebo interference and was successfully 
validated and achieved. The simple, fast and low cost 
developed methods, by non-aqueous titration and DUS, 
are excellent alternatives to sophisticated instrumental 
methods and can be easily applied in the quality control 
routine of such a popular drug, as SILC.
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